Skip to main content
Premium Trial:

Request an Annual Quote

GRIP Molecular: Edward Ludwig, Bruce Batten, Edward Gillen

GRIP Molecular has formed a board of directors with Edward Ludwig as its chairman. The board also comprises the company's Founder, President, and CSO Bruce Batten, and its CEO Edward Gillen. Ludwig is a former President and CEO of Becton Dickinson and currently serves on the boards of CVS Health and Boston Scientific. He is also a former board member of AdvaMed and a past chair of the health advisory board for the Johns Hopkins Bloomberg School of Public Health.

Batten previously was the founder and/or CEO of four technology starters and held executive positions at companies including Thermo Instruments, CyberOptica, and Advantek. Gillen was previously at BD where he held several positions including worldwide senior director, strategy and business development, Diabetes Care Division; global VP and GM, Surgical and Anesthesia Systems, Advanced Drug Delivery; and global business leader, Vaccine Delivery. 

Based in Minnesota, GRIP is developing an electronic biosensor for the detection of multiple biomarkers in a single test. The firm was founded in late 2019 and has licensed technology from the University of Minnesota, according to its website. Its first product will be targeted at upper respiratory infection with a planned launch in 2023.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.